Continuing medical education: ethical collaboration between sponsor and industry.
The quandary is, "How can the very different fiduciary responsibilities of physicians and pharmaceutical companies ethically coexist in a society where its healthcare system is under increasing financial scrutiny?" It is paradoxical that the number of states requiring continuing medical education for medical licensure has increased to 39, in the face of reduced federal funding and the squeeze of managed care. Despite industry's providing more than half of the funding required to sustain the increasing need for continuing medical education, some physicians claim it is inappropriate for continuing medical education sponsors to collaborate with pharmaceutical companies because of their vested interest in selling prescription medications. Is the integrity of the physician-patient relationship at risk? I will show that there are ethical standards in place, for professionals and industry, that are effectively maintaining the continuing medical education system in balance. Eliminating the current opportunities for collaboration between sponsors and commercial supporters would severely compromise the continuing medical education enterprise in the United States, ultimately, a disservice to patients, who expect their physicians to continue their medical education lifelong.
Wilson
Frederic S
FS
Proctor & Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040, USA. wilson.fs@pg.com
D000068:Accreditation; D000368:Aged; D003299:Cooperative Behavior; D004345:Drug Industry / Q000941:ethics; D004502:Education, Medical, Continuing / Q000191:economics / Q000941:ethics*; D004995:Ethics, Professional; D005260:Female; D005653:Fund Raising / Q000941:ethics; D006801:Humans; D007221:Industry / Q000941:ethics*; D009985:Orthopedics / Q000193:education / Q000941:ethics; D010024:Osteoporosis / Q000188:drug therapy; D014481:United States